Home
 Log in 
Table 1: Common medications used for seasonal allergic rhinitis (Normal version here)
Notes:
  1. Medications are ordered based on efficacy and adverse effects, however cost and patient preference are also important factors in choice of medicine.
  2. For pregnant or breastfeeding women use intranasal corticosteroid first-line (e.g. budesonide), if not tolerated or additional treatment is required, prescribe an oral antihistamine (e.g. loratadine), also consider the use of saline nasal spray as a “drug-free” alternative.5
  Adults Pregnant/breastfeeding Children

Intranasal antihistamines

Azelastine 0.14 mg/spray, one spray per nostril, twice daily (Azep )

Levocabastine 0.5 mg/mL, two sprays per nostril, twice daily (Livostin )

Azelastine – B3

Levocabastine – B3

From age five years: Azelastine 0.14 mg/spray, one spray per nostril, twice daily (Azep )

Oral antihistamines

Loratadine 10 mg once daily (Loraclear Hayfever Relief )

Fexofenadine 120–180 mg once daily (Telfast )

Cetirizine 5–20 mg once daily (Zetop ) (sedating above 10 mg daily)

Loratadine – B1

Cetirizine – B2

Fexofenadine – B2

From age two years:
Loratadine 1 mg/mL, 5 mL once daily (age >6 years, 10 mL) (LoraPaed )

From age two years:
Cetirizine 1 mg/mL, 5 mL once daily (age >6 years, 10 mL) (Cetirizine AFT )

Intranasal corticosteroids

Fluticasone 50–100 mcg/nostril once daily (Flixonase, Nasaclear )

Triamcinolone 55 mcg/nostril twice daily (Telnase )

Beclomethasone 50–100 mcg/nostril twice daily (Alanase )

Budesonide 50–100 mcg/nostril once daily (Butacort Aqueous )

Budesonide – A

Beclomethasone – B3

Fluticasone – B3

From age 12 years: Fluticasone 50 mcg/nostril once daily (Flixonase, Nasaclear )

From age six years: Budesonide 50 mcg/nostril once daily (Butacort Aqueous )

Intranasal decongestants

Xylometazoline 0.1%, one spray/nostril two to four times per day, maximum five days (Otrivin spray or drops )

Oxymetazoline 0.5 mg/mL (Drixine )

Xylometazoline

Not recommended unless benefit outweighs risk (Category C)

Xylometazoline 0.05%, one spray/nostril two to three times per day, max five days (Otrivin Junior spray or drops )

Oral corticosteroid

Prednisone 20–40 mg once daily for five to seven days

Prednisone – A

Prednisone 10 mg once daily for five to seven days

Intranasal anticholinergic

Ipratropium bromide 0.03% two sprays, two to three times daily (Apo-Ipravent )

Ipratropium bromide – B1

From age 12 years: Ipratropium bromide 0.03% two sprays, two to three times daily (Apo-Ipravent )

Intranasal sodium cromoglycate

Sodium cromoglycate Nasal Spray 4%, one spray/nostril two to four times per day

Sodium cromoglycate – A

From age six years: Sodium cromoglycate Nasal Spray 4%, one spray/nostril two to four times per day

Ocular antihistamines

Levocabastine, one drop per eye, three times per day (Livostin eye drops )

Lodoxamide, one drop per eye, four times per day (Lomide )

Olopatadine, one drop per eye, two times per day (Patanol )

Ketotifen, one drop per eye, two times per day (Zaditen )

Naphazoline + pheniramine (Visine, Naphcon-A )

Antazoline + naphazoline (Albalon-A )

N.B. naphazoline can cause rebound hypaeremia (redness) if used for longer than ten days

Lodoxamide – B1

Olopatadine – B1

Ketotifen – B1

Levocabastine – B3

From age six years: Levocabastine, one drop per eye, three times per day (Livostin eye drops )

From age four years: Lodoxamide, one drop per eye, four times per day (Lomide )

From age three years: Olopatadine, one drop per eye, two times per day (Patanol )

From age three years: Ketotifen, one drop per eye, two times per day (Zaditen )

Australian Drug Evaluation Committee classification of drugs in pregnancy (summarised)11

Category A No evidence of harmful effects to the human foetus.
Category B1 No evidence of harmful effects to the human foetus observed, but limited number of human studies. Animal studies have shown no increased risk of foetal harm.
Category B2 No evidence of harmful effects to the human foetus observed, but limited number of human or animal studies.
Category B3 No evidence of harmful effects to the human foetus observed, but limited number of human studies. Animal studies have shown evidence of increased risk of foetal harm, the significance of which is uncertain in humans.
Category C May cause, or may be suspected of causing, harmful effects on the human foetus or neonate without causing malformations. Drug should only be used if benefit outweighs risk

= Fully subsidised, = Partly subsidised, = Not subsidised

 Home  |  About us  |  Contact us  |  Site map  | |  Return to top 
© bpacnz 2011